Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Mitral Valve Repair With the Chord-X System: A Long Term Evaluation

← catalyst calendar

NCT07413926 · readout ≤ 2,781 d

Sponsored by Artivion Inc. (industry) · AORT — their whole pipeline →.

Phase
Status
Not yet recruiting
Study type
Observational
Enrollment
110estimated
Sites
4
Countries
Italy, United Kingdom, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
StartJun 2026estimatedWhen the study began enrolling
Primary completionMar 2034estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionJun 2034estimatedThe whole study's end, after follow-up
First posted2026-02-17actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-02-20actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Mitral Regurgitation (MR)

Intervention

  • Device: Chord-X system implant

Primary outcome

what the primary-completion date above is the date OF
Recurrent Mitral Regurgitation
measured The primary endpoint will be evaluated at all time points in the study, through 10 years post-implant.

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AORT's whole pipeline · Catalyst calendar · Every registered study · What changed